As demand for GLP-1 medications skyrockets, patients are increasingly targeted with compounded knockoffs that are not FDA approved and do not meet federal safety or quality standards. Doug spoke with Leigh Verbois, formerly with the FDA, who said that research shows patients using these products are twice as likely to be hospitalized compared with those on FDA-approved treatments—underscoring urgent risks for millions of Americans seeking weight-loss or diabetes care. www.Buysaferx.pharmacy